Vildagliptin/metformin, fixní léková kombinace

Číslo: 1 / 2010 (Obsah)
Rubrika: Profily léčiv
Obor: Diabetologie
Autoři: MUDr. Radomíra Kožnarová, CSc.
1MUDr. Jiří Slíva
Autoři - působiště: Klinika diabetologie, Centrum diabetologie, Institut klinické a experimentální medicíny, Praha
1 Ústavy farmakologie 2. a 3. LF UK, Praha
Citace: 1 Saenz A, Fernandez-Esteban I, Mataix A, et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;CD002966. 2 Formoso G, De Filippis EA, Michetti N, et al. Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects. Diabetes Metab Res Rev 2008;24:231–7. 3 Detaille D, Guigas B, Chauvin C et al. Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes 2005;54:2179–87. 4 Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res 2008;5:157–67. 5 Henness S, Keam SJ. Vildagliptin. Drugs 2006;66:1989–2001. 6 He YL, Wang Y, Bullock JM, et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol 2007;47:633–41. 7 Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005;90:4888–94. 8 Fonseca V, Rao AD. DPP-4 inhibitors as a new target of action for type 2 diabetes mellitus: a focus on vildagliptin. Expert Rev Endocrinol Metab 2007;2:567–72. 9 Lauster CD, McKaveney TP, Muench SV. Vildagliptin: a novel oral therapy for type 2 diabetes mellitus. Am J Health Syst Pharm 2007;64:1265–73. 10 Ahren B. Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties. Expert Opin Invest Drugs 2006;15:431–42. 11 Duttaroy A, Voelker F, Zhang X. The DPP-4 inhibitor vildagliptin increases b cell mass in rodents. Diabetologia 2005;48:A178. 12 Ahren B, Pacini G, Tura A, et al. Improved meal-related insulin processing contributes to the enhancement of β-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. Horm Metab Res 2007;39:826–9. 13 Mari A, Scherbaum WA, Nilsson PM, et al. Characterization of the influence of vildagliptin on model-assessed-cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab 2008;93:103–9. 14 Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007;92: 1249–55. 15 Utzschneider KM, Tong J, Montgomery B, et al. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 2008;31:108–13. 16 Azuma K, Radikova Z, Mancino J, et al. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase-4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 2008;93:459–64. 17 Vella A, Bock G, Giesler PD, et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 2007;56:1475–80. 18 Tahrani AA, Piya MK, Barnett AH. Drug evaluation: Vildagliptin-metformin single-tablet combination. Adv Ther 2009;26: 138–54. 19 He YL, Serra D, Wang Y, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet 2007;46:577–88. 20 He YL, Flannery B, Campestrini J, et al. Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers. Curr Med Res Opin 2008;24:1703–9. 21 He YL, Sabo R, Picard F, et al. Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes. Curr Med Res Opin 2009;25:1265–72. 22 Serraj K, Vogel T, Federici L, et al. Food-cobalamin syndrome. Presse Med 2009;38:55–62.

Souhrn

Vildagliptin (obrázek 1) je molekula ze skupiny inhibitorů dipeptidylpeptidázy-4 (DPP-4) – látek, které jsou využívány pro svůj hypoglykemizující účinek jako perorální antidiabetika u pacientů s diabetem 2. typu. V České republice je registrován pod obchodním názvem Galvus (Novartis) v tabletách s obsahem 50 mg účinné látky. Nejběžnější lékovou kombinací je využití synergických účinků vildagliptinu a metforminu.

Literatura

1 Saenz A, Fernandez-Esteban I, Mataix A, et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;CD002966. 2 Formoso G, De Filippis EA, Michetti N, et al. Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects. Diabetes Metab Res Rev 2008;24:231–7. 3 Detaille D, Guigas B, Chauvin C et al. Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes 2005;54:2179–87. 4 Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res 2008;5:157–67. 5 Henness S, Keam SJ. Vildagliptin. Drugs 2006;66:1989–2001. 6 He YL, Wang Y, Bullock JM, et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol 2007;47:633–41. 7 Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005;90:4888–94. 8 Fonseca V, Rao AD. DPP-4 inhibitors as a new target of action for type 2 diabetes mellitus: a focus on vildagliptin. Expert Rev Endocrinol Metab 2007;2:567–72. 9 Lauster CD, McKaveney TP, Muench SV. Vildagliptin: a novel oral therapy for type 2 diabetes mellitus. Am J Health Syst Pharm 2007;64:1265–73.
10
Ahren B. Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties. Expert Opin Invest Drugs 2006;15:431–42.
11
Duttaroy A, Voelker F, Zhang X. The DPP-4 inhibitor vildagliptin increases b cell mass in rodents. Diabetologia 2005;48:A178.
12
Ahren B, Pacini G, Tura A, et al. Improved meal-related insulin processing contributes to the enhancement of β-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. Horm Metab Res 2007;39:826–9.
13
Mari A, Scherbaum WA, Nilsson PM, et al. Characterization of the influence of vildagliptin on model-assessed-cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab 2008;93:103–9.
14
Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007;92: 1249–55.
15
Utzschneider KM, Tong J, Montgomery B, et al. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 2008;31:108–13.
16
Azuma K, Radikova Z, Mancino J, et al. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase-4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 2008;93:459–64.
17
Vella A, Bock G, Giesler PD, et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 2007;56:1475–80.
18
Tahrani AA, Piya MK, Barnett AH. Drug evaluation: Vildagliptin-metformin single-tablet combination. Adv Ther 2009;26: 138–54.
19
He YL, Serra D, Wang Y, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet 2007;46:577–88.
20
He YL, Flannery B, Campestrini J, et al. Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers. Curr Med Res Opin 2008;24:1703–9.
21
He YL, Sabo R, Picard F, et al. Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes. Curr Med Res Opin 2009;25:1265–72.
22
Serraj K, Vogel T, Federici L, et al. Food-cobalamin syndrome. Presse Med 2009;38:55–62.

Celý článek je dostupný jen pro předplatitele časopisu


Přihlášení

 

Předplatné

Více o předplatném

 
 
 
Jste odborný pracovník ve zdravotnictví?
Jsem odborníkem ve smyslu §2a Zákona č. 40/1995 Sb., o regulaci reklamy, ve znění pozdějších předpisů, čili jsem osobou oprávněnou předepisovat léčivé přípravky nebo osobou vydávat léčivé přípravky.

Potvrzuji, že jsem se seznámil/a s definicí odborník
dle zákona č. 40/1995 Sb.
Potvrzuji, že jsem se seznámil/a s riziky, jimž se jiná osoba než odborník vystavuje, vstoupí-li na stránky určené pro odborníky